

# FramingHam

*on systemic fungal infections*

Liposomal amphotericin B—the future

*Journal of Antimicrobial Chemotherapy*, 2022 November 25; 77(Suppl 2):ii21–34

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies

*Scientific Reports*, 2023 April 25; 13(1):6730

Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study

*Journal of Infection*, 2023 July; 87(1):46–53

The use of galactomannan antigen assays for the diagnosis of invasive pulmonary aspergillosis in the hematological patient: a systematic review and meta-analysis

*Journal of Fungi*, 2023 June 15; 9(6):674

Worldwide emergence of fluconazole-resistant *Candida parapsilosis*: current framework and future research roadmap

*The Lancet Microbe*, 2023 June; 4(6):e470–80

Worsening spread of *Candida auris* in the United States, 2019 to 2021

*Annals of Internal Medicine*, 2023 April; 176(4):489–95

Increased hospitalizations involving fungal infections during COVID-19 pandemic, United States, January 2020–December 2021

*Emerging Infectious Diseases*, 2023 July; 29(7):1433–37

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM CANDIDA III multinational European observational cohort study

*The Lancet Infectious Diseases*, 2023 June; 23(6):751–61

ISSUE 3, 2023

Hospital-treated serious and invasive aspergillosis and candidiasis infections during the COVID-19 pandemic:

a retrospective analysis of Hospital Episode Statistics data from England

*BMJ Open*, 2023 May 30; 13(5):e070537

A pathology-based case series of influenza- and COVID-19-associated pulmonary aspergillosis: the proof is in the tissue

*American Journal of Respiratory and Critical Care Medicine*, 2023 August 1; 208(3):301–11

The antifungal pipeline for invasive fungal diseases: what does the future hold?

*Expert Review of Anti-Infective Therapy*, 2023 June; 21(6):577–94

Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies:

2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

*Journal of Antimicrobial Chemotherapy*, 2023 August 2; 78(8):1813–26

**CURRENT TITLES**

Framingham *on anaesthesiology and surgery*  
 Framingham *on atherosclerosis*  
 Framingham *on benign haematology*  
 Framingham *on breast cancer*  
 Framingham *on cystic fibrosis*  
 Framingham *on dermatology*  
 Framingham *on fertility*  
 Framingham *on gastroenterology*  
 Framingham *on haematological malignancies*  
 Framingham *on HIV/AIDS*  
 Framingham *on lung cancer*  
 Framingham *on multiple myeloma*  
 Framingham *on multiple sclerosis*  
 Framingham *on neurology*  
 Framingham *on ovarian cancer*  
 Framingham *on rheumatology*  
 Framingham *on urology*  
 and many more...

**DISCLAIMER**

The abstracts in this publication are prepared with care to reflect the views expressed by the author or authors of the original source material. These views are not necessarily those of the publisher or the sponsor. While every care is taken to avoid errors, these cannot always be avoided; readers are advised to independently validate any data and recommendations contained herein before acting on this information. The publisher and the sponsor disclaim any responsibility or liability for the accuracy of such information.

**ADVISORY BOARD**

Paul E. Verweij, MD PhD  
 Professor of Clinical Mycology,  
 Consultant Microbiologist &  
 Head of the Department of  
 Medical Microbiology,  
 University Medical Center  
 Nijmegen,  
 and Nijmegen University Center  
 for Infectious Diseases,  
 Nijmegen, the Netherlands

**OUR PURPOSE**

The Framingham series of publications is designed to meet clinical specialists' need for a reliable guide to the most important articles appearing in their field.

Each issue presents an authoritative selection from the recently published literature, with the emphasis on evidence-based medicine. Articles are recommended for inclusion by Framingham's editorial office and an advisory board headed by key opinion leaders in the relevant clinical area.

Framingham's team of medical writers prepares original abstracts of these articles, in a structured format that presents the main points at a glance. Our aim is to convey the essence of each article in a concise but readable style.

Issues are published every three to six months.

**Framingham****Editor**

Kathy Croom

**Medical Writers (this issue)**

Stephen Bartlett  
 Claire Beveridge  
 Catherine Booth  
 Jane Grills  
 David Newton

**Art Design**

Jan van Halm

**Layout and Printing**

Drukmeesters,  
 Zwijndrecht, the Netherlands

**Publishing Director**

Evelien Enter

**Publisher**

Waldemar H.G. Dobrowolski

**Framingham bv**

Postbus 1593  
 1200 BN Hilversum  
 The Netherlands  
[www.framinghampublishers.com](http://www.framinghampublishers.com)

Framingham *on systemic fungal infections* is supported by  
**Gilead Sciences Netherlands BV**,  
 Amsterdam, the Netherlands

© 2023 Framingham bv

## LIPOSOMAL AMPHOTERICIN B—THE FUTURE

*Journal of Antimicrobial Chemotherapy*, 2022 November 25; 77(Suppl 2):ii21–34

AUTHORS: HOENIGL M, LEWIS R, VAN DE VEERDONK FL, VERWEIJ PE, CORNELLY OA

CENTRE FOR CORRESPONDENCE: DIVISION OF INFECTIOUS DISEASES, DEPARTMENT OF INTERNAL MEDICINE, MEDICAL UNIVERSITY OF GRAZ, GRAZ, AUSTRIA

**BACKGROUND & AIM:** The importance of empirical or pre-emptive broad-spectrum antifungal treatment is expected to increase in the future, and liposomal amphotericin B will therefore remain a gold standard for the primary treatment of unspecified invasive fungal infections (IFIs) and as a targeted therapy against specific pathogens. The aim of this review was to explore the role of liposomal amphotericin B in the next 30 years.

**ARTICLE TYPE:** Expert review.

**FINDINGS:** One major advantage of liposomal amphotericin B is its comparative lack of drug–drug interactions, and this is expected to become even more important as additional therapies emerge for patients at risk of IFIs, such as small-molecule kinase inhibitors (SMKIs) for patients with cancer. At present, there is a lack of robust data on the risk of IFIs in these patients, and the physician’s clinical judgement is therefore vital in identifying those patients who should have routine diagnostic screening or antifungal prophylaxis. Nonetheless, it is known that nearly all SMKIs are metabolized through the cytochrome P3A4/A5 system, which means drug–drug interactions with triazole antifungals are likely (coadministration should therefore be avoided where possible), highlighting the need for

oral broad-spectrum antifungal therapies that do not inhibit human CYP3A4/A5. In the meantime, intravenous echinocandins are often recommended as prophylaxis to avoid drug interactions.

The past few decades have seen the emergence of resistance to most classes of antifungal therapy – the exception being a low level of acquired resistance to amphotericin B in *Aspergillus* species. In addition, new drug-resistant species (e.g. *Candida auris*) are emerging as a result of both in-host and environmental resistance selection. An initial step in managing drug resistance would be to understand the local epidemiology of azole resistance within specific hospitals, regions or countries. However, this remains poorly documented, and improved surveillance programmes are urgently needed to help guide empirical treatment choices and institutional treatment recommendations for patients with IFIs. In addition, minimum inhibitory concentrations are important in guiding personalized therapy, but often do not correlate with outcomes in clinical practice, and susceptibility testing therefore needs to improve.

**CONCLUSION:** With its broad range of action, low resistance and low rate of drug–drug interactions, liposomal amphotericin B is expected to remain a mainstay of antifungal treatment in the years to come.

# POST-HOC ANALYSIS OF THE SAFETY AND EFFICACY OF ISAVUCONAZOLE IN OLDER PATIENTS WITH INVASIVE FUNGAL DISEASE FROM THE VITAL AND SECURE STUDIES

*Scientific Reports, 2023 April 25; 13(1):6730*

AUTHORS: HAMED K, ENGELHARDT M, KOVANDA LL, HUANG JJ, YAN J, ARAM JA

CENTRES: BASILEA PHARMACEUTICA INTERNATIONAL LTD., ALLSCHWIL, SWITZERLAND; ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC., NORTHBROOK, ILLINOIS; PFIZER INC., NEW YORK, USA; PFIZER, 10645848 PBG CHINA MEDICAL, BEIJING, CHINA

**BACKGROUND & AIM:** Invasive fungal diseases are life-threatening infections that present a major risk of death and long-term morbidity for immunocompromised and at-risk patients, such as the elderly. Isavuconazole is a broad spectrum triazole used in the treatment of invasive aspergillosis and invasive mucormycosis. This study evaluated the safety and efficacy of isavuconazole in patients aged  $\geq 65$  years.

**STUDY DESIGN:** Post hoc analysis.

**ENDPOINTS:** Adverse events (safety), overall response and all-cause mortality (efficacy).

**METHOD:** Data from two prospective clinical trials involving patients with invasive fungal diseases (VITAL and SECURE) were analysed; patient-level data were stratified according to age ( $< 65$  and  $\geq 65$  years). The safety and efficacy of isavuconazole was evaluated alone (VITAL) or compared to voriconazole (SECURE).

**RESULTS:** Among 146 patients enrolled in VITAL, 116 were  $< 65$  years and 30 were  $\geq 65$  years; of the 516 patients in SECURE, 391 were  $< 65$  years and 125 were  $\geq 65$  years. The majority of patients in both trials reported adverse events. Among isavuconazole recipients, the incidence of serious adverse events (SAEs) was greater in patients aged  $\geq 65$  versus those aged  $< 65$  years in both studies; in VITAL, SAEs were reported in 76.7% versus 56.9% of these age groups, while in SECURE the proportions were 61.9% versus 49.0%. In SECURE, a similar rate of SAEs was reported in those aged  $\geq 65$  years compared to those aged  $< 65$  years in the voriconazole arm (58.1% versus 57.4%). In VITAL, all-cause mortality at day 42 after starting isavuconazole was higher in patients aged  $\geq 65$  years compared to age  $< 65$  years, and overall response at the end of treatment was lower (table). In SECURE, similar all-cause mortality was seen in both age groups and both treatment arms (table), while the overall response rate at age  $\geq 65$  years was lower than at age  $< 65$  years, in both the isavuconazole and voriconazole arms (table).

**CONCLUSIONS:** Isavuconazole had a better safety and efficacy profile in patients aged  $< 65$  years than in older patients. However, the safety profile of isavuconazole appeared better than that of voriconazole in both age groups.

Efficacy in patients aged  $\geq 65$  years versus  $< 65$  years treated with isavuconazole (ISA) or voriconazole (VOR)

Study	Treatment / age group	All-cause mortality (%)	Overall response (%)
VITAL	ISA $\geq 65$ years	30.0	27.6
	ISA $< 65$ years	13.8	46.8
SECURE	ISA $\geq 65$ years	20.6	23.7
	ISA $< 65$ years	17.9	39.0
	VOR $\geq 65$ years	22.6	32.0
	VOR $< 65$ years	19.4	37.5



# BREAKTHROUGH INVASIVE FUNGAL INFECTION AMONG PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: A NATIONAL, PROSPECTIVE, AND MULTICENTRE STUDY

*Journal of Infection*, 2023 July; 87(1):46–53

AUTHORS: PUERTA-ALCALDE P, MONZÓ-GALLO P, AGUILAR-GUISADO M, ET AL.

CENTRE FOR CORRESPONDENCE: INFECTIOUS DISEASES DEPARTMENT, HOSPITAL CLÍNIC-IDIBAPS,  
BARCELONA, SPAIN

**BACKGROUND & AIM:** Widespread use of antifungal agents in the treatment of patients with haematological malignancies has been linked to an increased incidence of breakthrough invasive fungal infections (BtIFI). A lack of knowledge regarding the causes of BtIFI may increase the incidence of infections caused by rare fungi and the chance of antifungal resistance developing in causative species. The aim of this study was to characterize the causes and outcomes of BtIFI in a real-world cohort of patients with haematological malignancies.

**STUDY DESIGN:** Prospective, multicentre, cohort study.

**ENDPOINTS:** Clinical and microbiological outcomes.

**METHOD:** All BtIFI episodes in adults with haematological malignancies at 13 Spanish university hospitals were prospectively recorded over 36 months (2017–2020). BtIFI was defined as occurring when there was first clinical suspicion of IFI, according to revised EORTC/MSG definitions, following  $\geq 7$  days of antifungal treatment. Fungal isolates were identified in blood and respiratory samples using mass spectrometry or pan-fungal polymerase chain reaction and sequencing analysis. A diagnosis of proven BtIFI followed fungal isolation in blood culture, positive culture of a sterile site with radiological or clinical significance,

or histopathological findings from a sterile specimen. Kaplan–Meier survival curves were used to assess mortality.

**RESULTS:** Among 121 BtIFI episodes, 33.9% were proven, 43.8% were probable and 22.3% were possible. The most common underlying disease was acute myeloid leukaemia (67/121 episodes; 55.4%), and the most common prior antifungals were posaconazole (32.2%) and echinocandins (28.9%). The most frequent BtIFI was invasive aspergillosis (55/121 episodes; 45.5%) followed by candidaemia (19.0%), with 62.1% of *Aspergillus* isolates being identified as non-*fumigatus* and 86.9% of *Candida* species as non-*albicans*. Other causes of BtIFI included mucormycosis (5.8%), other moulds (5.0%) and other yeasts (4.1%). Among proven and probable episodes of BtIFI, the most common cause was lack of activity of prior antifungal treatment (63/94 episodes; 67.0%). In 27/94 (28.7%) of these episodes, the causative fungi were intrinsically resistant to the prior antifungal treatment. The 100-day mortality rate was 47.1%, and BtIFI was the cause of death (or a significant contributory factor) in 61.4% of cases.

**CONCLUSIONS:** In this Spanish cohort of patients with haematological malignancies, BtIFI were mainly caused by non-*fumigatus* *Aspergillus* and non-*albicans* *Candida* species. Patients had a poor prognosis.

# THE USE OF GALACTOMANNAN ANTIGEN ASSAYS FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS IN THE HEMATOLOGICAL PATIENT: A SYSTEMATIC REVIEW AND META-ANALYSIS

*Journal of Fungi*, 2023 June 15; 9(6):674

AUTHORS: BUKKEMS LM, VAN DOMMELEN L, REGIS M, VAN DEN HEUVEL E, NIEUWENHUIZEN L  
CENTRES: MAXIMA MEDICAL CENTRE, VELDHOVEN; ZIEKENHUIS GELDERSE VALLEI, EDE; AND MATHEMATICS AND COMPUTER SCIENCE, EINDHOVEN UNIVERSITY OF TECHNOLOGY, EINDHOVEN, THE NETHERLANDS

**BACKGROUND & AIM:** Individuals with haematological malignancies are at risk of opportunistic infections such as invasive pulmonary aspergillosis (IPA), and early diagnosis and treatment are important for the best chance of survival. A diagnosis of IPA can be made by looking for galactomannan (an *Aspergillus*-specific marker) in serum and bronchoalveolar lavage (BAL) fluid, but the appropriate cutoff value for the optical density index (ODI) for galactomannan in diagnosing IPA is a matter of debate. The aim of this study was to examine the most recent evidence on ODI cut-off values for diagnosing IPA in patients with haematological malignancies.

**STUDY DESIGN:** Systematic review and meta-analysis.

**ENDPOINTS:** Primary: pooled sensitivity and specificity of serum and BAL galactomannan. Secondary: sensitivity and specificity per ODI.

**METHOD:** A search of the PubMed, Embase and Cochrane databases identified

27 studies that reported the use of galactomannan Platelia ELISA in serum or BAL fluid for diagnosing IPA in adults with haematological malignancies, and used the EORTC/MSG categories of proven/probable/possible/no IPA. Data were extracted from eligible studies and pooled using a generalized linear mixed model with binomial distribution.

**RESULTS:** Analysis of 15 serum studies (total  $n=2568$ ), regardless of the cutoff value or study design, gave an overall sensitivity of 0.76 and specificity of 0.92 for galactomannan for diagnosing proven/probable IPA versus no IPA, and sensitivity and specificity of 0.45 and 0.91, respectively, for diagnosing proven/probable/possible IPA. There were insufficient studies available for pooled analysis of ODI cutoffs of 1.0 and 1.5, but values for a cutoff of 0.5 are shown in the table. Analysis of 12 BAL studies (total  $n=1090$ ) provided overall sensitivity of 0.80 and specificity of 0.95 for diagnosing proven/probable IPA versus no IPA, and values of 0.49 and 0.95, respectively, for proven/probable/possible IPA. Sensitivity and specificity for ODI cutoffs of 0.5 and 1.0 are shown in the table.

**CONCLUSION:** Based on available data, galactomannan ODI cutoffs of 0.5 for serum and 1.0 for BAL fluid were most suitable for diagnosing proven/probable IPA in patients with haematological malignancies.

Sensitivity and specificity of galactomannan for diagnosing proven/probable invasive pulmonary aspergillosis (IPA) versus no IPA according to optical density index (ODI) cut-off

		Sensitivity	Specificity
Serum	Overall	0.76	0.92
	ODI cut-off 0.5	0.92	0.84
Bronchoalveolar lavage	Overall	0.80	0.95
	ODI cut-off 0.5	0.75	0.88
	ODI cut-off 1.0	0.75	0.96

# WORLDWIDE EMERGENCE OF FLUCONAZOLE-RESISTANT *CANDIDA PARAPSILOSIS*: CURRENT FRAMEWORK AND FUTURE RESEARCH ROADMAP

*The Lancet Microbe*, 2023 June; 4(6):e470–80

AUTHORS: DANESHNIA F, DE ALMEIDA JÚNIOR JN, ILKIT M, LOMBARDI L, PERRY AM, GAO M, NOBILE CJ, EGGER M, PERLIN DS, ZHAI B, HOHL TM, GABALDÓN T, COLOMBO AL, HOENIGL M, ARASTEHFAR A

CENTRES FOR CORRESPONDENCE: DIVISION OF INFECTIOUS DISEASES, ECMM EXCELLENCE CENTER, DEPARTMENT OF INTERNAL MEDICINE, MEDICAL UNIVERSITY OF GRAZ, GRAZ, AUSTRIA AND DIVISION OF INFECTIOUS DISEASES, MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MASSACHUSETTS, USA

**BACKGROUND & AIMS:** Since 2018, outbreaks of candidaemia caused by fluconazole-resistant strains of *Candida parapsilosis* have been reported. Multidrug-resistant and echinocandin-resistant strains have also been reported since 2020, which could potentially replace strains that are susceptible to current azole-based treatment strategies, posing a public health threat given the limited number of antifungal drugs available for clinical use. The aim of this review was to summarize current knowledge regarding the global emergence of fluconazole-resistant *C. parapsilosis* strains.

**ARTICLE TYPE:** Review.

**FINDINGS:** *C. parapsilosis* is one of the most prevalent candidaemia-causing species, with infections primarily occurring in patients admitted to intensive care units, neonates and people with COVID-19, cancer or who have received transplants. Outbreaks are generally caused by horizontal transmission from the environment to patients via the hands of healthcare workers, or via contaminated intravenous solutions.

Over the last 3 years, fluconazole-resistant *C. parapsilosis* strains have been reported to outcompete fluconazole-susceptible ones and persist in hospital settings, causing severe sporadic outbreaks among azole-naïve patients and increased mortality compared with patients with fluconazole-susceptible infections. *ERG11* mutations and overexpression of *ERG11* are believed

to underpin fluconazole resistance, although some studies have reported that >60% of resistant strains do not carry *ERG11* mutations. There is also evidence that strains with intermediate fluconazole minimum inhibitory concentrations (MICs) might develop resistance by increasing the *CDR1* copy number.

Echinocandin-resistant strains often have mutations in the catalytic subunit of  $\beta$ -glucan synthase, and a concept of heteroresistance has been proposed, where a small subpopulation of isolates could tolerate high echinocandin concentrations, reducing the efficacy of prophylaxis. Studies have shown that *TAC1*<sup>L518F</sup> and *FKS1*<sup>S656P</sup> polymorphisms in *C. parapsilosis* genes increase the fluconazole MIC and confer pan-echinocandin resistance, respectively. Additionally, some *C. parapsilosis* strains have been shown to form biofilms on abiotic and biotic surfaces that protect them from the host immune response and antifungal drugs.

Regular global monitoring of fluconazole- and echinocandin-resistant *C. parapsilosis* outbreaks, and characterization of the underlying mechanisms, is needed to aid the development of new antifungal agents and molecular assays for environmental screening and skin swab sampling.

**CONCLUSION:** The emergence of fluconazole- and echinocandin-resistant strains of *C. parapsilosis* emphasizes the need for global monitoring and new classes of antifungal agents.



## WORSENING SPREAD OF *CANDIDA AURIS* IN THE UNITED STATES, 2019 TO 2021

*Annals of Internal Medicine*, 2023 April; 176(4):489–95

AUTHORS: LYMAN M, FORSBERG K, SEXTON DJ, CHOW NA, LOCKHART SR, JACKSON BR, CHILLER T  
CENTRE: MYCOTIC DISEASES BRANCH, DIVISION OF FOODBORNE, WATERBORNE, AND ENVIRONMENTAL DISEASES, CENTERS FOR DISEASE CONTROL AND PREVENTION, ATLANTA, GEORGIA, USA

**BACKGROUND & AIM:** *Candida auris* infections were first reported in the USA in 2016 and notification of clinically confirmed cases became mandatory in 2019. Nosocomial transmission is a significant problem, and the threat is increased by the emergence of antifungal-resistant cases. The aim of this study was to give a national overview, focusing on *C. auris* spread over the period 2019–2021.

**STUDY DESIGN:** Retrospective analysis of national surveillance and antimicrobial resistance testing data.

**ENDPOINTS:** Incidence of *C. auris*-positive cases and antifungal-resistant cases.


**METHOD:** The study reviewed all confirmed and probable clinical and colonization-screening-derived cases notified to the CDC, state and local health departments

from 2013 to the end of 2021. Data on antifungal resistance to azoles, polyenes and echinocandins were obtained from the seven CDC regional testing centres, which have run a *C. auris* testing programme since 2017.

**RESULTS:** Annual clinical case numbers increased from 53 in 2016 (the year of first report) to 1471 in 2021, with a cumulative total of 3270 cases. Clinical cases increased by 44% from 2018 to 2019, by 59% between 2019 and 2020 and by a further 95% during 2021 (figure). Most positive cases were detected in post-acute-care facilities. In 2020, cases were reported for the first time in eight US states, compared with six states in 2019. Colonization-screening testing increased markedly from 2019 (19,756) to 2021 (>40,000), with a drop in testing during 2020 due to the COVID-19 pandemic, but the positivity rate remained constant at about 8%. A cumulative total of 7413 screening cases were reported (figure). By 2020, 85.7% of isolates were azole-resistant and 25.6% were polyene-resistant. Resistance to echinocandins was still low (1.2%) but had increased significantly since 2018, with the greatest number of resistant cases occurring in the northeastern USA.

**CONCLUSIONS:** *C. auris* infections are growing numerically and geographically in the US, with an increase in echinocandin-resistance that is potentially concerning. Implementing rigorous infection control protocols is the best means of controlling spread.

Number of clinical and colonization-screening cases of *Candida auris* reported per month in the USA between 2016 and 2021



## INCREASED HOSPITALIZATIONS INVOLVING FUNGAL INFECTIONS DURING COVID-19 PANDEMIC, UNITED STATES, JANUARY 2020–DECEMBER 2021

*Emerging Infectious Diseases*, 2023 July; 29(7):1433–37

AUTHORS: GOLD JA, ADJEI S, GUNDLAPALLI AV, HUANG YA, CHILLER T, BENEDICT K, TODA M  
CENTRES: CENTERS FOR DISEASE CONTROL AND PREVENTION, ATLANTA, GEORGIA, USA

**BACKGROUND & AIM:** COVID-19 infection is a risk factor for invasive fungal infections, and deaths due to fungal infection increased in the USA during the COVID-19 pandemic. However, many fungal infections are not notifiable diseases in the USA and so broader data on healthcare burden and resource utilization are lacking. The aim of this study was to evaluate fungal disease-related hospital admissions during the COVID-19 pandemic, to improve public health planning and clinical practice.

**STUDY DESIGN:** Retrospective analysis of hospital records database.

**ENDPOINTS:** Hospitalization, length of stay, intensive care unit admission, mechanical ventilation, in-hospital death.

**METHOD:** Data were extracted from the Premier Healthcare Database, Special COVID-19 Release of de-identified patient records from more than 1000 US hospitals. Data from 2019–2020 (pre-COVID) were compared with January 2020–December

2021 (COVID period). COVID-19-associated fungal hospitalizations were defined as those in which both infections occurred during the same hospitalization.

**RESULTS:** Rates of hospitalization (per 10,000 admissions) with a fungal infection increased from 22.3 in 2019 to 25.0 in 2020 and 26.8 in 2021, with a significant ( $p < 0.01$ ) increase in rate for all fungal pathogens except *Pneumocystis*, *Cryptococcus* and the category “other specified fungi”. During the COVID period, 13.4% of fungal hospitalizations were COVID-19-associated. Rates of COVID-19-associated fungal hospitalization (per 10,000 admissions) increased from 2020 to 2021, particularly for *Aspergillus* (7.9 to 18.9; +58.2%,  $p < 0.01$ ) and *Blastomyces* (0.2 to 0.5; +65.6%,  $p < 0.01$ ), but not for *Candida* (11.2 to 10.9; –2.4%,  $p = 0.69$ ) infections. Compared with patients without COVID-19, co-infected patients were more likely to be Hispanic/Latino, older and male, and had a longer hospital stay, and greater need for intensive care and mechanical ventilation, and risk of in-hospital death (table). Among co-infected patients, the highest mortality rates were in those with aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%) and unspecified mycoses (59.0%).

**CONCLUSIONS:** The burden of fungal infections in those coinfecting with COVID-19 suggests that comprehensive surveillance of such pathogens is warranted.

Demographics and outcomes of patients hospitalized with fungal infections according to COVID-19 status

Parameter	COVID-19-associated	Not COVID-19-associated	<i>p</i>
Median age, years	63	61	<0.01
Male sex, %	59.9	57.5	<0.01
Hispanic/Latino ethnicity, %	18.8	11.7	<0.01
Median length of stay, days	21	9	<0.01
ICU care, %	70.0	35.5	<0.01
Invasive mechanical ventilation, %	64.4	22.5	<0.01
In-hospital death, %	48.5	12.3	<0.01

# GUIDELINE ADHERENCE AND SURVIVAL OF PATIENTS WITH CANDIDAEMIA IN EUROPE: RESULTS FROM THE ECMM CANDIDA III MULTINATIONAL EUROPEAN OBSERVATIONAL COHORT STUDY

*The Lancet Infectious Diseases*, 2023 June; 23(6):751–61

AUTHORS: HOENIGL M, SALMANTON-GARCÍA J, EGGER M, ET AL., FOR THE ECMM CANDIDA III STUDY GROUP  
CENTRE FOR CORRESPONDENCE: DIVISION OF INFECTIOUS DISEASES, DEPARTMENT OF INTERNAL MEDICINE,  
MEDICAL UNIVERSITY OF GRAZ, GRAZ, AUSTRIA

**BACKGROUND & AIMS:** Despite advances in management, invasive candidiasis including candidaemia is associated with high mortality in the hospital setting. The European Confederation of Medical Mycology (ECMM) Quality of Clinical Candidaemia Management (EQUAL *Candida*) scores were developed to measure the quality of disease management as reflected by adherence to guidelines published by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the Infectious Diseases Society of America (IDSA). The aim of the *Candida* III study was to assess how adherence to guidelines for the diagnosis and management of candidaemia correlates with patient outcomes.

**STUDY DESIGN:** European multicentre observational cohort study.

**ENDPOINTS:** EQUAL *Candida* score and correlation with outcomes.

**METHOD:** Data for the first 10 consecutive adult patients who presented with culture-proven candidaemia (defined according to ESCMID criteria) after 1 July 2018 at each of 64 participating hospitals in 20 European countries were entered into the ECMM *Candida* Registry. The number of patients and number of centres per country were stratified by population size. EQUAL *Candida* scores were assessed. Independent predictors of mortality were identified using Cox regression analysis.

**RESULTS:** Among the 632 participants, the median age was 65 years and 58% were male. The most common risk factors for candidaemia were underlying malignancy (39% of patients), intensive care unit (ICU) admission (37%) and recent major surgery (26%). Overall 90-day mortality was 43%. Independent baseline predictors of mortality were ICU admission (adjusted hazard ratio 1.71), increasing age (aHR 1.37), increases in Charlson comorbidity index scores (aHR 1.09 per point) and the causative pathogen being *Candida tropicalis* (aHR 1.78). Lower EQUAL *Candida* score was an independent predictor of mortality after adjustment for known baseline predictors of mortality. Among patients who survived more than 7 days after diagnosis, a decrease of one point in the EQUAL *Candida* score was associated with an increase in the risk of death of 8% and 9% in patients with or without a central venous catheter, respectively. Lack of performance or completion of ophthalmoscopy (aHR 2.19), echocardiography (aHR 1.77), treatment for  $\geq 14$  days after first negative blood culture (aHR 3.64) or step-down therapy to fluconazole (aHR 1.71), as recommended in the guidelines, were also predictors of mortality.

**CONCLUSION:** A lower EQUAL *Candida* score was an independent predictor of mortality, indicating that greater adherence to clinical guideline recommendations for the diagnosis and management of patients with candidaemia may increase survival.

# HOSPITAL-TREATED SERIOUS AND INVASIVE ASPERGILLOSIS AND CANDIDIASIS INFECTIONS DURING THE COVID-19 PANDEMIC:

## A RETROSPECTIVE ANALYSIS OF HOSPITAL EPISODE STATISTICS DATA FROM ENGLAND

*BMJ Open*, 2023 May 30; 13(5):e070537

AUTHORS: SUNG AH, KIELY G, SINGH JK, THOMAS S, LOUGH J, SMITH M  
CENTRE FOR CORRESPONDENCE: MEDICAL AFFAIRS, PFIZER LTD, TADWORTH, UK

**BACKGROUND & AIM:** Serious and invasive fungal infections, such as invasive aspergillosis (IA) and invasive candidiasis, are linked to adverse outcomes in seriously ill patients, but the burden they impose on the UK healthcare system is not well understood. COVID-19 infection increases patient susceptibility through both direct and indirect effects, such as immunosuppression and a requirement for mechanical ventilation. The aim of this analysis was to investigate the impact of COVID-19 infection on the healthcare burden of invasive aspergillosis and invasive candidiasis in hospitals in England.

**STUDY DESIGN:** Retrospective analysis of Hospital Episode Statistics (HES).

**ENDPOINTS:** Patient case numbers, mean length of stay (MLOS), admission to a critical care unit (CCU), length of CCU stay, readmission within 30 days and failed discharge (readmission within 7 days).

**METHOD:** Anonymized data including patient characteristics, diagnoses, comorbidities and healthcare utilization, including CCU admission and readmissions, for patients with a diagnosis of serious aspergillosis or invasive candidiasis were extracted from NHS Digital HES records for the period March 2018 to October 2021. March 2020 was taken as the starting point of the COVID-19 pandemic period in the UK.

**RESULTS:** Before the COVID period, 6255 patients were recorded with aspergillosis and 3445 with candidiasis. From March 2020 onwards, there were 4350 aspergillosis patients and 2385 candidiasis patients without COVID-19 and a further 600 patients (8.2%) with either fungal infection who also had a COVID-19 diagnosis. Hospital admissions decreased at the start of the COVID-19 pandemic and monthly patient counts with IA showed a similar drop (24.8%), recovering after 12 months; invasive candidiasis patient counts, however, showed only a small decline (3.2%). Patients with aspergillosis plus COVID-19 infection had a markedly longer MLOS than those with aspergillosis alone (20.2 versus 9.0 days), but the same was not true for invasive candidiasis patients (27.2 versus 28.8 days). Readmissions within 30 days increased for patients with a COVID-19 diagnosis in addition to a fungal infection (from 8.6% to 12.6% for aspergillosis and from 2.5% to 3.7% for candidiasis), as did failed discharges. A COVID-19 diagnosis also increased the proportion of patients admitted to the CCU (from 13.2% to 52.5% for aspergillosis patients and from 37.1% to 60.0% for candidiasis) and the length of stay in the CCU.

**CONCLUSIONS:** Coinfection with invasive aspergillosis or candidiasis and COVID-19 increased disease burden and the need for critical care and worsened outcomes.



## A PATHOLOGY-BASED CASE SERIES OF INFLUENZA- AND COVID-19-ASSOCIATED PULMONARY ASPERGILLOSIS: THE PROOF IS IN THE TISSUE

*American Journal of Respiratory and Critical Care Medicine*, 2023 August 1; 208(3):301–11

AUTHORS: VANDERBEKE L, JACOBS C, FEYS S, RESÉNDIZ-SHARPE A, DEBAVEYE Y, HERMANS G, HUMBLÉT-BARON S, LAGROU K, MEERSSEMAN P, PEETERMANS M, SELDESCHACHTS L, VANSTAPEL A, VANDE VELDE G, VAN WIJNGAERDEN E, WILMER A, VERBEKEN E, DE HERTOOGH G, WAUTERS J  
CENTRE FOR CORRESPONDENCE: MEDICAL INTENSIVE CARE UNIT, UNIVERSITY HOSPITALS LEUVEN, LEUVEN, BELGIUM

**BACKGROUND & AIM:** Influenza-associated pulmonary aspergillosis is a potentially life-threatening invasive disease, often confirmed histopathologically, that develops in up to 25% of influenza patients admitted to intensive care. COVID-19-associated pulmonary aspergillosis is a similar condition, but is supported by less evidence of invasiveness and conflicting findings regarding its incidence. The aim of this study was to compare the two, making use of autopsy and antemortem findings.

**STUDY DESIGN:** Retrospective, single-centre case series.

**ENDPOINTS:** Incidence of virus-associated pulmonary aspergillosis (VAPA); histopathological findings.

**METHOD:** The study examined records and tissue samples of patients with PCR-proven influenza or COVID-19-associated respiratory failure who died after admission to the ICU of a Belgian tertiary care hospital and underwent autopsy. Patients were classified based on clinical and pathological evidence of VAPA.

**RESULTS:** The study examined samples from a cohort of 44 patients (23 coronavirus-infected and 21 influenza virus-infected) who underwent autopsy. Of these 44 patients, 21 (48%) were classified before death as having “probable VAPA”, of whom 11/21 (52%) had evidence of

invasive pulmonary fungal disease on autopsy, despite having been given antifungal treatment. Overall, proven VAPA was established at autopsy in 12 patients, six with influenza and six with COVID-19. Two histological patterns of fungal growth were observed: unimpeded fungal bronchopneumonia with a high fungal load and large areas of fungal necrosis (2/11 patients) and impeded fungal bronchopneumonia with a low fungal load and dispersed, fragmented hyphae surrounded by acutely inflamed/necrotic lung tissue (9/11 patients). The pattern observed did not correlate with the underlying virus type. Galactomannan (GM) testing of bronchoalveolar lavage (BAL) fluid was found to be the most sensitive method for detecting VAPA in the antemortem period (92%, with a specificity of 64%), ahead of BAL culture (58%, specificity 93%) and serum GM testing (33%, specificity 94%). The autopsy-proven incidence of VAPA in these patients (12% for influenza-infected patients and 8% for those with coronavirus infection) was somewhat higher than reported elsewhere.

**CONCLUSIONS:** Invasive fungal infection may be more common in critically ill patients with viral pneumonia (influenza or COVID-19) than previously suspected, as demonstrated by histological findings at autopsy. However, the dispersed pattern of impeded fungal growth commonly seen could make it difficult to detect.



## THE ANTIFUNGAL PIPELINE FOR INVASIVE FUNGAL DISEASES: WHAT DOES THE FUTURE HOLD?

*Expert Review of Anti-Infective Therapy*, 2023 June; 21(6):577–94

AUTHORS: NEOH CF, JEONG W, KONG DC, SLAVIN MA

CENTRE FOR CORRESPONDENCE: NATIONAL CENTRE FOR INFECTIONS IN CANCER, PETER MACCALLUM CANCER CENTRE, MELBOURNE, AUSTRALIA

**BACKGROUND & AIMS:** Only five classes of antifungal agent are available for routine clinical management of invasive fungal diseases (IFD), all of which have limitations. The rising prevalence of antifungal-resistant strains has contributed to a significant increase in the incidence of IFD in recent years, and novel antifungal agents are needed. This review considered five antifungal agents for IFD that are currently in phase 2 or 3 clinical trials (fosmanogepix, ibrexafungerp, olorofilm, rezafungin and opelconazole).

**ARTICLE TYPE:** Review.

**FINDINGS:** Fosmanogepix is an N-phosphono-oxymethylene prodrug that is converted to its active moiety (manogepix) by systemic phosphatases and inhibits glycosylphosphatidylinositol-anchored wall transfer protein 1. Of note, manogepix displays potent activity against rarer yeast and difficult-to-treat fungi species, and although generally inactive against Mucorales it was effective against *Rhizopus arrhizus*-caused mucormycosis in a murine model. It displays a synergistic interaction with calcineurin inhibitors against clinically relevant fungal species, which could be of use in immunocompromised patients.

Ibrexafungerp has a similar mechanism of action to echinocandins and may have a lower risk of drug–drug interactions than triazoles. It has potent *in vitro* activity against *Candida* spp. and azole-susceptible

and -resistant *Aspergillus fumigatus* sensu stricto strains. It has well established efficacy in treating vulvovaginal candidiasis.

Olorofilm inhibits a fungal dihydro-oroate dehydrogenase enzyme needed for cell-wall integrity and can penetrate the blood–brain barrier, potentially making it suitable for treating CNS infections. It is active against multi-resistant *Aspergillus* species and against *Coccidioides immitis* and *C. posadasii*, and has demonstrated antibiofilm activity against *A. fumigatus* and *Lomentospora prolificans*.

Rezafungin is an echinocandin with potent activity against *C. auris* in mice and against cryptic *Aspergillus* species with reduced susceptibility to other antifungal agents *in vitro*. It is being evaluated in patients undergoing haematopoietic stem-cell transplantation due to its broad-spectrum activity against *Candida* spp. and *Aspergillus* spp.

The novel triazole opelconazole was developed for nebulizer-mediated pulmonary administration and may be particularly effective against localized pulmonary infections. It has potent broad-spectrum activity *in vitro*, including against *R. arrhizus*, although it lacks activity against other Mucorales.

**CONCLUSION:** Although these five novel antifungal agents show potential as IFD treatments, further research is needed to define their benefits and appropriate use.

# PRIMARY PROPHYLAXIS OF INVASIVE FUNGAL DISEASES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: 2022 UPDATE OF THE RECOMMENDATIONS OF THE INFECTIOUS DISEASES WORKING PARTY (AGIHO) OF THE GERMAN SOCIETY FOR HAEMATOLOGY AND MEDICAL ONCOLOGY (DGHO)

*Journal of Antimicrobial Chemotherapy*, 2023 August 2; 78(8):1813–26

AUTHORS: STEMLER J, MELLINGHOFF SC, KHODAMORADI Y, SPRUTE R, CLASSEN AY, ZAPKE SE, HOENIGL M, KRAUSE R, SCHMIDT-HIEBER M, HEINZ WJ, KLEIN M, KOEHLER P, LISS B, KOLDEHOFF M, BUHL C, PENACK O, MASCHMEYER G, SCHALK E, LASS-FLÖRL C, KARTHAUS M, RUHNKE M, CORNELLY OA, TESCHNER D  
CENTRE FOR CORRESPONDENCE: DEPARTMENT OF INTERNAL MEDICINE II, UNIVERSITY HOSPITAL WÜRZBURG, WÜRZBURG, GERMANY

**BACKGROUND & AIM:** Haematological malignancies are associated with a high risk of invasive fungal disease (IFD), which is a significant cause of morbidity and mortality in these individuals. The risk is highest in patients with long-lasting neutropenia, such as those with acute myeloid leukaemia (AML), myelodysplastic syndrome during remission-induction chemotherapy, or severe aplastic anaemia. The most common pathogens are *Aspergillus* and *Candida* species, and the standard of care for those with long-lasting neutropenia is mould-active antifungal prophylaxis. In 2017, the German Society of Haematology and Medical Oncology published recommendations on the primary prophylaxis of IFDs in patients with haematological malignancies. This article updates those recommendations in light of new evidence on epidemiology and treatment approaches.

**ARTICLE TYPE:** Clinical recommendations.

**FINDINGS:** Antifungal prophylaxis is still strongly recommended for patients with haematological malignancies and long-lasting neutropenia (<500 cells/ $\mu$ L for >7 days), regardless of the underlying disease. Individuals with a shorter duration of neutropenia are not at increased risk of IFD and should therefore not receive antifungal prophylaxis. The drug of choice for mould-active prophylaxis is still posaconazole. The results of three large retrospective cohort

studies published since 2017 are consistent with previous prospective studies of this drug. Isavuconazole and voriconazole now have moderate support, and there are low recommendations for fluconazole and itraconazole, but other azoles are not recommended.

There is still insufficient evidence to recommend novel treatment options such as CAR-T cell therapy or AML-targeted treatments. However, the results of several recent trials of micafungin prophylaxis mean that the recommendation for this drug's use has been upgraded to moderate. Other new recommendations include the use of non-pharmaceutical measures to help prevent IFD, including high-efficiency particulate air filters, advice to give up smoking, and installation during hospital construction of measures to prevent airborne fungal spread, while neutropenic diets are not recommended. There is a potential for interaction between antifungal prophylaxis and novel targeted therapies, in particular between triazoles which inhibit CYP3A4/5 and drugs that are metabolized via cytochrome p450. Accordingly, the dose of venetoclax should be reduced when used concomitantly with strong CYP3A4-inhibiting antifungals.

**CONCLUSION:** Updated recommendations are provided on the use of antifungal prophylaxis in patients with haematological malignancies.

# Meer leren over **invasieve schimmelinfecties (IFI)**?



## ECCMID Highlights verslag

Arts-microbioloog Karin van Dijk (Amsterdam UMC) was aanwezig tijdens ECCMID in Kopenhagen. Zij presenteerde haar mycologie highlights op 22 mei j.l. tijdens een online sessie. Heb je deze sessie gemist? Zo vraag je het verslag aan:

**Ontvang het verslag digitaal of in print. Scan de QR-code en geef je voorkeur aan.**



Alle Framingham uitgaven zijn ook digitaal beschikbaar op [www.ifihub.nl](http://www.ifihub.nl)

## Toegang tot cases, studies en factsheets

Op [www.ifihub.nl](http://www.ifihub.nl) staan veel relevante publicaties en presentaties over invasieve schimmelinfecties. Download en verbreed uw kennis!

Invasive Fungal Infections  
**Knowledge Hub**



Antifungal Treatments



Latest Literature



Case Studies



Clinical Field stories



Guidelines



Congress Highlights and Videos

## Laten we samenwerken

Heeft u interesse in een op-maat-gemaakte klinische les over invasieve schimmelinfecties? Neem contact met ons op om mogelijkheden in uw ziekenhuis te bespreken.



**Elize Veenstra**

Field Brand Manager IFI  
[Elize.Veenstra@gilead.com](mailto:Elize.Veenstra@gilead.com)



**Ruth Van Daele**

Medical Manager IFI  
[Ruth.VanDaele@gilead.com](mailto:Ruth.VanDaele@gilead.com)